ArticleNucleic acids research2016
Cell-based high-throughput compound screening reveals functional interaction between oncofetal HMGA2 and topoisomerase I.
Article in Nucleic acids research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- SMC1A is required for fate determinations of human spermatogonial stem cells and male fertility by interacting with YBX1 and stabilizing HMGA2 mRNA via an mCell death and differentiation · 2026Article
- Reciprocal constraint couples architectural protein abundance and pericentromeric satellite expansion.bioRxiv : the preprint server for biology · 2026Article
- Kinetically Trapped Ligand Binding in DNA Tandem Repeats.Biochemistry · 2026Article
- Treatment of stage IV colorectal cancer: A retrospective cohort study assessing whether failure of first‑line treatment indicates failure of second‑line treatment.Molecular and clinical oncology · 2025Article
- Decoding high mobility group A2 protein expression regulation and implications in human cancers.Discover oncology · 2024Review
- Selection of Natural Compounds with HMGA-Interfering Activities and Cancer Cell Cytotoxicity.ACS omega · 2023Article
- Review
- Nuclear High Mobility Group A2 (HMGA2) Interactome Revealed by Biotin Proximity Labeling.International journal of molecular sciences · 2023Article
- Chromatin Architectural Factors as Safeguards against Excessive Supercoiling during DNA Replication.International journal of molecular sciences · 2020Review
- Oncofetal HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology.Molecular oncology · 2019Article
- The chromatin structuring protein HMGA2 influences human subtelomere stability and cancer chemosensitivity.PloS one · 2019Article
- Binding of high mobility group A proteins to the mammalian genome occurs as a function of AT-content.PLoS genetics · 2017Article
- Oncofetal HMGA2 effectively curbs unconstrained (+) and (-) DNA supercoiling.Scientific reports · 2017Article
- Dovitinib enhances temozolomide efficacy in glioblastoma cells.Molecular oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HMGA2 is an important chromatin factor that interacts with DNA via three AT-hook domains, thereby regulating chromatin architecture and transcription during embryonic and fetal development. The protein is absent from differentiated somatic cells, but aberrantly re-expressed in most aggressive human neoplasias where it is causally linked to cell transformation and metastasis. DNA-binding also enables HMGA2 to protect cancer cells from DNA-damaging agents. HMGA2 therefore is considered to be a prime drug target for many aggressive malignancies. Here, we have developed a broadly applicable cell-based reporter system which can identify HMGA2 antagonists targeting functionally important protein domains, as validated with the known AT-hook competitor netropsin. In addition, high-throughput screening can uncover functional links between HMGA2 and cellular factors important for cell transformation. This is demonstrated with the discovery that HMGA2 potentiates the clinically important topoisomerase I inhibitor irinotecan/SN-38 in trapping the enzyme in covalent DNA-complexes, thereby attenuating transcription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.